Varma Mutual Pension Insurance Co Sells 2,800 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Varma Mutual Pension Insurance Co cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,088 shares of the biopharmaceutical company’s stock after selling 2,800 shares during the period. Varma Mutual Pension Insurance Co’s holdings in Regeneron Pharmaceuticals were worth $13,190,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of REGN. Dodge & Cox increased its position in shares of Regeneron Pharmaceuticals by 18.9% during the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after buying an additional 724,562 shares during the period. AQR Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals by 528.7% during the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock valued at $405,596,000 after buying an additional 606,612 shares during the period. Invesco Ltd. increased its position in shares of Regeneron Pharmaceuticals by 38.0% during the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after buying an additional 408,649 shares during the period. Caisse de depot et placement du Quebec increased its position in shares of Regeneron Pharmaceuticals by 115.4% during the third quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company’s stock valued at $260,051,000 after buying an additional 247,780 shares during the period. Finally, Man Group plc increased its position in shares of Regeneron Pharmaceuticals by 257.6% during the third quarter. Man Group plc now owns 271,707 shares of the biopharmaceutical company’s stock valued at $152,773,000 after buying an additional 195,724 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Guggenheim upped their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research report on Friday. Cantor Fitzgerald reiterated an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $826.59.

Regeneron Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ REGN opened at $709.21 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $74.98 billion, a price-to-earnings ratio of 17.28, a PEG ratio of 1.60 and a beta of 0.30. The business has a 50-day moving average of $756.81 and a 200-day moving average of $737.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the previous year, the firm earned $8.22 earnings per share. Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.05 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 3,874 shares of company stock valued at $3,013,262. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.